Rapamycin
Rapamycin is an mTOR inhibitor primarily used as an immunosuppressant, with emerging evidence suggesting potential benefits in extending lifespan & improving aging biomarkers in humans.
Evidence last reviewed: 05 Apr 2026
Not a routine supplement — not recommended for self-directed use.
Information here is educational only, not a recommendation to use. See our Safety page.
Evidence is from research or clinical settings — does not imply safety outside supervised contexts.
Moderate evidence indicates rapamycin positively affects healthspan metrics and aging-related physiological parameters. However, the evidence for topical applications is limited, and more research is needed to fully understand its long-term effects in humans.
Aging-related physiological improvementsAdults with aging-related diseases · Systematic reviewModerate
Rapamycin & its derivatives improved physiological parameters associated with aging in the immune, cardiovascular, & integumentary systems.
Vascular anomaly treatmentChildren with lymphatic malformations · Systematic reviewModerate
Sirolimus was highly effective in treating vascular tumors & lymphatic malformations, with significant clinical improvement.
Healthspan metricsAdults · RCTModerate
Rapamycin influenced safety & healthspan metrics positively after one year.
Skin aging markersAdults with skin aging · Randomized trialLow
Topical rapamycin reduced markers of senescence & aging in human skin.